INTRODUCTION
============

Estimating the lifespan of erythrocytes is useful for the differential diagnosis of anemia, as it is known that the erythrocyte lifespan in hemolytic patients is shortened \[[@r1]\]. Previously, obtaining the lifespan or mean age of erythrocytes was very difficult; therefore, it was seldom measured. Furthermore, supply of ^51^Cr, which is needed for measuring erythrocyte lifespan, was ceased in Japan in 2015 due to low demand. This left Japanese doctors unable to measure the erythrocyte lifespan of patients by means of ^51^Cr. Biotin-labeling \[[@r2], [@r3]\] is also used to measure the erythrocyte lifespan, however its procedure is very laborious as well, requiring aseptic labeling of the erythrocytes and repeated blood samplings. Breath carbon monoxide (CO) measurement \[[@r4], [@r5]\] also may be useful to estimate erythrocyte turnover; however, this technique cannot be applied to smokers. We have proposed a method to estimate erythrocyte mean age from HbA1c and average glucose \[[@r6]\]. However, the method needed a glycation constant to be determined by another method. Some indices such as reticulocyte and haptogloblin were not sensitive enough to indicate mild hemolysis. Cases with latent hemolysis were reported which showed normal reticulocyte and normal haptogloblin levels, and yet, they showed shortened erythrocyte lifespan \[[@r7]--[@r9]\].

Creatine in the cells is maintained by creatine transporters. Deficiency in these transporters leads to symptoms \[[@r10], [@r11]\]. Young erythrocytes have adequate transporter activity resulting in intracellular creatine being tens of times higher than in plasma. However, the activity of the transporter gradually diminishes, so that old erythrocytes cannot maintain this concentration gradient.

Erythrocyte creatine (EC) has been demonstrated to be an excellent indicator of hemolysis \[[@r12], [@r13]\]. Estimation of mean erythrocyte age (*M~RBC~*) using EC would be more convenient than the ^51^Cr method, as it requires only one blood sample. Though an increase in EC value has been correlated with shorter lifespan of erythrocytes, EC value itself has not previously been used for the estimation of *M~RBC~* directly. An estimation of *M~RBC~* would be more useful for quantitative assessment of patients than simple EC value. Moreover, *M~RBC~* derived by EC may be comparable with *M~RBC~* derived by other methods.

In this study, we aimed to formulate an equation to obtain *M~RBC~* from EC concentration based on a model.

RESULTS
=======

Relationship between *M~RBC~* and log~*e*~ EC
---------------------------------------------

A significant linear relationship (*r* = −0.9475, df =19, *t* = 12.92, *p* = 7.368 × 10^−11^) was observed between ^51^Cr-derived *M~RBC~* and log*~e~ EC* ([Figure 1](#f1){ref-type="fig"}). The relationship appears to be mono-exponential which is concurrent with the prediction by our model (Supplement) that the relationship would be bi- or mono-exponential.

![**Relationship between *M~RBC~* and log~*e*~ EC.** A significant linear relationship was observed. A *red closed circle* denotes a standard value; *M~RBC~* = 60 days, *EC* = 1.4μmol/g Hb. A *black line* denotes a regression line. *EC*, erythrocyte creatine; *M~RBC~*, mean erythrocyte age.](aging-12-103193-g001){#f1}

A regression line was as follows.
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A standard value of *EC* of 1.4 μmol/g Hb gives an *M~RBC~* of 58.14 days.

Equation (2) accurately estimated *M~RBC~* from *EC* values ([Figure 2](#f2){ref-type="fig"}).

![***M~RBC~* estimated by *EC* and ^51^Cr.** EC derived *M~RBC~* showed excellent estimation. An *orange dotted line* denotes line of identification (*y* = *x*). A *black line* denotes a regression line. *EC*, erythrocyte creatine; *M~RBC~*, mean erythrocyte age.](aging-12-103193-g002){#f2}

DISCUSSION
==========

The current study successfully established a reliable method of estimating *M~RBC~* from *EC* based on a creatine model (Supplement). We would be able to determine a glycation constant for the method to estimate erythrocyte mean age from HbA1c and average glucose \[[@r14]\].

Although Fehr et al. \[[@r13]\] divided patients into a severe hemolytic disease group and a group with milder forms of hemolysis, our model suggested that logarithm of *EC* may combine the two groups ([Figure 3](#f3){ref-type="fig"}). The regression formula passed close to a standard value of *EC*, 1.4 μmol/g Hb and 60 days of *M~RBC~*, which proves the validity of the formula.

![**Relationship between *EC* and *M~RBC~* in the groups with severe and mild hemolytic disease.** (**A**) The two groups show differing regression lines on a normal scale. (**B**) The two groups are unified on a semi-logarithmic scale. The *Red circles* represent mild group, *sky blue* the severe group according to Fehr et al. \[[@r13]\]. *EC*, erythrocyte creatine; *M~RBC~*, mean erythrocyte age.](aging-12-103193-g003){#f3}

It cannot be determined which wing of the two lines (Supplement) the observed line of the log~*e*~ EC-- *M~RBC~* relationship is on; *i.e.* whether the slope of the graph represents the rate constant for creatine diffusion (λ~1~) or the rate constant for decline in creatine transporter (λ~2~). Another equation may need to be developed for value ranges not explored in this study.

The devised method was formulated entirely based on the previously presented data from only 21 patients.

This method should be verified by further study with various hematological diseases including thalassemia and hereditary spherocytosis. Estimation of *M~RBC~* from ^51^Cr half-life may not be optimal, although we believe that it would be tolerable. The EC transporter activity function, *Be*^−λ2*t*^ relies solely on the assumption that the number of transporters reduces overtime randomly due to erythrocytes' lack of nucleus. However, the linear relationship between log~*e*~ EC and *M~RBC~* confirms the assumption. The EC measuring method of Fehr et al. \[[@r13]\] used a diacetyl-*l*-naphthol chemical reaction, which is less sensitive than the recently developed *N*-methylcarbamoyl derivative of methylene blue, 10-*N*-methylcarbamoyl-3,7-*bis*(dimethylamino)phenothiazine (MCDP) enzyme method \[[@r15]\]. Further study on the validity of our proposed formula would be best done in a country where ^51^Cr is available.

CONCLUSIONS
===========

Our equation does allow calculation of *M~RBC~* based on EC, which has practical applications such as the diagnosis of anemia.

MATERIALS AND METHODS
=====================

Patients
--------

Data from 21 patients with hemolytic anemia, that was published by Fehr et al. \[[@r13]\], was examined. As this is a re-analysis study, approval by the institutional review board was not required.

Data conversion
---------------

We estimated *M~RBC~* by multiplying the half life of ^51^Cr by 2.61. As human erythrocytes do not obey the Poisson process \[[@r16]\], the term "half-life" is not entirely suitable for erythrocytes. Fehr et al. \[[@r13]\] determined ^51^Cr half-life, the elution-corrected ^51^Cr half-life, and the mean cell lifespan. The mean cell lifespan was not recorded in their table. The elution-corrected ^51^Cr half-life would provide an estimate of *M~RBC~*, considering that normal erythrocytes in a human have a similar lifespan \[[@r16]\]. However, their elution-corrected ^51^Cr half-life seems less concordant with EC rank. Complicated procedures sometimes reduce the stability of the system. Therefore, we chose the simple uncorrected ^51^Cr half-life in the same way as Fehr et al. \[[@r13]\]. Considering that *M~RBC~* for normal erythrocytes is about 60 days, and the normal range of ^51^Cr half-life was 23 -- 27 days, multiplying ^51^Cr half-life by 2.61 (= 60/23) provides a good estimation of *M~RBC~* in practice.

The units for erythrocyte creatine concentration used by Fehr et al. \[[@r13]\] were mg/dL of red cells. We converted these into μmol/g Hb by the following equation, assuming mean cell hemoglobin concentration (MCHC) is 33g/dL. The molecular weight of creatine is 131.15. While MCHC varies naturally and decreases in iron deficiency anemia, variability in MCHC is generally low.
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Data analysis
-------------

Data on *EC* and *M~RBC~* were analyzed with a spreadsheet software, Excel ^®^ 365 (Microsoft Corporation, Redmond, WA, USA).

Logarithms of *EC* and *M~RBC~* were plotted based on our model (Supplement).

Supplementary Material
======================

The authors would like to thank Ms. Natalie Okawa and Editage for English language editing of this manuscript.

**AUTHOR CONTRIBUTIONS:** M. Kameyama contributed to theory, the analysis of the data, writing the original draft, and funding acquisition. M. Koga contributed to conceptualization, the analysis of the data, and supervision. T.O. contributed to advise on the nature of EC. All the authors have read and approved the final manuscript.

**CONFLICTS OF INTEREST:** M.Kameyama received research funding from Fujifilm RI Pharma, which stopped supply of ^51^Cr in Japan, Nihon Med-Physics, and Daiichi-Sankyo. TO received research funding from Asahi Kasei Pharma.

**FUNDING:** This study is partly supported by Grants-in-Aid for Scientific Research, 18K07488 for M. Kameyama.
